259 related articles for article (PubMed ID: 9832387)
1. Selective cardiodepressant activity of fluodipine, a fluorenone-1,4-dihydropyridine derivative.
Budriesi R; Aicardi G; Campana G; Spampinato S; Zaza A; Bisi A; Rampa A; Valenti P; Chiarini A
Eur J Pharmacol; 1998 Oct; 359(2-3):161-70. PubMed ID: 9832387
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment for vascular selectivity of a new dihydropyridine derivative, NB-818.
Hattori Y; Fukao M; Houzen H; Qi F; Yamada Y; Kanno M
Eur J Pharmacol; 1996 Apr; 301(1-3):99-106. PubMed ID: 8773452
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity.
Shibata S; Satake N; Kodama I; Hester RK; Wang CG; Jino H; Hojo M; Tatsumi H; Gandhi V; Jones DJ
Eur J Pharmacol; 1991 Oct; 203(3):337-44. PubMed ID: 1773820
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.
Yamaura T; Kase N; Kita H; Uematsu T
Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect.
Masumiya H; Shijuku T; Tanaka H; Shigenobu K
Eur J Pharmacol; 1998 May; 349(2-3):351-7. PubMed ID: 9671117
[TBL] [Abstract][Full Text] [Related]
7. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
[TBL] [Abstract][Full Text] [Related]
8. Calcium antagonistic and antiarrhythmic actions of CPU-23, a substituted tetrahydroisoquinoline.
Dong H; Sheng JZ; Lee CM; Wong TM
Br J Pharmacol; 1993 May; 109(1):113-9. PubMed ID: 8495235
[TBL] [Abstract][Full Text] [Related]
9. [Effects of furyl-dihydropyridine on action potential ventricular myocardium of rabbit in vivo and isolated guinea pig left atrium in vitro].
Liu DQ; Zhou SS; Zhao DH; Sheng BH
Zhongguo Yao Li Xue Bao; 1993 Mar; 14(2):164-7. PubMed ID: 8352012
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of FR34235, a new dihydropyridine slow channel blocker, in isolated rabbit myocardium and aorta.
Furuta T; Shibata S; Kodama I; Yamada K
J Cardiovasc Pharmacol; 1983; 5(5):836-41. PubMed ID: 6195473
[TBL] [Abstract][Full Text] [Related]
11. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine.
Miyoshi K; Miyake H; Ichihara K; Kamei H; Nagasaka M
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):119-25. PubMed ID: 9007851
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of NPK-1886, a new dihydropyridine compound with calcium entry blocking activity.
Nagura J; Murayama B; Harada N; Suzuki K; Miyano T; Yajima M; Takeya K
Jpn J Pharmacol; 1986 Mar; 40(3):399-409. PubMed ID: 3712868
[TBL] [Abstract][Full Text] [Related]
13. [Vasodilator effects of LF 2.0254, a new 1,4-dihydropyridine. Comparison with nifedipine].
Pruneau D; Roy F; Brown NL
Therapie; 1989; 44(3):203-8. PubMed ID: 2781506
[TBL] [Abstract][Full Text] [Related]
14. Ca2+ channel inhibition by a new dihydropyridine derivative, S11568, and its enantiomers S12967 and S12968.
Randle JC; Lombet A; Nagel N; Abraham C; Aptel H; Peglion JL; Renaud JF
Eur J Pharmacol; 1990 Nov; 190(1-2):85-96. PubMed ID: 1706275
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular properties of LF 2.0254, a new potent vasoselective calcium channel blocker with a slow onset of action.
Pruneau D; Roy F; Brown NL
Fundam Clin Pharmacol; 1990; 4(2):223-43. PubMed ID: 2112508
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors.
Burges RA; Gardiner DG; Gwilt M; Higgins AJ; Blackburn KJ; Campbell SF; Cross PE; Stubbs JK
J Cardiovasc Pharmacol; 1987 Jan; 9(1):110-9. PubMed ID: 2434785
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
18. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
[TBL] [Abstract][Full Text] [Related]
19. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists.
Nakaya H; Hattori Y; Nakao Y; Kanno M
Eur J Pharmacol; 1988 Jan; 146(1):35-43. PubMed ID: 3350058
[TBL] [Abstract][Full Text] [Related]
20. Effects of mibefradil, a selective T-type Ca2+ channel antagonist, on sino-atrial node and ventricular myocardia.
Masumiya H; Kase J; Tanaka Y; Tanaka H; Shigenobu K
Res Commun Mol Pathol Pharmacol; 1999; 104(3):321-9. PubMed ID: 10741382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
